|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT01393249 |
|
Date of registration:
|
12/07/2011 |
|
Primary sponsor: |
|
|
Public title:
|
Prediction and Prevention of PEG-Asparaginase Associated Pancreatitis, Hepatotoxicity and Hyperlipidemia in Children With Acute Lymphoblastic Leukemia
|
|
Scientific title:
|
Prediction and Prevention of PEG-Asparaginase Associated Pancreatitis, Hepatotoxicity and Hyperlipidemia in Children With Acute Lymphoblastic Leukemia |
|
Date of first enrolment:
|
July 2011 |
|
Target sample size:
|
40 |
|
Recruitment status: |
Recruiting |
|
URL:
|
http://clinicaltrials.gov/show/NCT01393249 |
|
Study type:
|
Observational |
|
Study design:
|
Observational Model: Cohort, Time Perspective: Prospective
|
|
|
Countries of recruitment
|
|
Denmark
| | | | | | | |
|
Contacts
|
|
Name:
|
Raheel Raja, M.D. |
|
Address:
|
|
|
Telephone:
|
+4526137089 |
|
Email:
|
raja_sahib@yahoo.com |
|
Affiliation:
|
|
|
|
Name:
|
Raheel Raja, M.D. |
|
Address:
|
|
|
Telephone:
|
+45 26137089 |
|
Email:
|
raja_sahib@yahoo.com |
|
Affiliation:
|
|
| |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- IR- or SR- type ALL, and treatment with Peg-Asparaginase
Exclusion Criteria:
- HR ALL, and changing subgroup from IR or SR to HR
Age minimum:
1 Year
Age maximum:
18 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Acute Lymphoblastic Leukemia
|
|
Asparaginase
|
|
Pancreatitis
|
|
Secondary ID(s)
|
|
PEGASPALL240778
|
|
RR240778PEGASP
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|